%0 Journal Article
%T 溃疡性结肠炎治疗药物研究进展
Research Progress of Therapeutic Drugs for Ulcerative Colitis
%A 曹肖颖
%A 魏志凤
%J Pharmacy Information
%P 429-437
%@ 2160-4452
%D 2024
%I Hans Publishing
%R 10.12677/pi.2024.135051
%X 溃疡性结肠炎(ulcerative colitis, UC)是一种慢性炎症性肠道疾病，病变部位主要累及直肠和结肠。UC发病机制尚不明确，缺乏根治性药物。目前，临床中的常用药物主要包括氨基水杨酸类、糖皮质激素和免疫抑制剂等，但多存在一系列不良反应，导致临床使用受限。近年来，新型生物制剂和小分子抑制剂通过特异性作用于炎症反应中的关键分子在UC治疗中显示出良好的疗效和应用前景，包括抗TNF-α单克隆抗体、抗整合素α4β7抗体、抗IL-12/IL-23抗体、Janus激酶抑制剂和鞘氨醇-1-磷酸受体调节剂等。本文就UC的治疗药物作一综述，以促进其治疗策略的优化和进步。
Ulcerative colitis (UC) is a chronic inflammatory bowel disease, mainly involving the lesion sites of rectum and colon. The UC pathogenesis is unclear, and lacks the radical drugs. At present, the commonly used drugs mainly consist of aminosalicylic acids, glucocorticoids and immunosuppressants, etc., but there are a series of adverse reactions, resulting in limited clinical use. In recent years, new biological agents and small molecule inhibitors have shown good efficacy and application prospects in the treatment of UC by specifically acting on key molecules in the inflammatory response, including anti-TNF-α monoclonal antibodies, anti-integrin α4β7 antibodies, anti-IL-12/IL-23 antibodies, Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators. This article reviews the existing therapeutic drugs for UC, in order to promote the optimization and progress of its treatment strategy.
%K 溃疡性结肠炎，
%K 生物制剂，
%K 小分子抑制剂，
%K 中药
Ulcerative Colitis
%K Biological Agents
%K Small Molecule Inhibitors
%K Chinese Medicine
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=96793